Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

Completed

Conditions: Plaque Psoriasis, Psoriatic Arthritis

First Posted Date: 2020-11-04

Last Posted Date: 2021-07-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4978

Registration Number: NCT04614831

Locations: 🇨🇭
Novartis Investigational Site, Basel, Switzerland

A First-in-Human Study of CEE321 in Adult Subjects

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: CEE321

First Posted Date: 2020-11-02

Last Posted Date: 2022-10-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT04612062

Locations: 🇯🇵
Novartis Investigative Site, Hachioji, Tokyo, Japan

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Phase 3

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: brolucizumab

First Posted Date: 2020-10-22

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 248

Registration Number: NCT04597632

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Completed

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)

Interventions: Drug: Mayzent

First Posted Date: 2020-10-20

Last Posted Date: 2024-02-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 451

Registration Number: NCT04593927

Locations: 🇯🇵
Novartis Investigative Site, Tokushima, Japan

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Phase 2

Recruiting

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)

Interventions: Drug: Alpelisib
Drug: Placebo

First Posted Date: 2020-10-19

Last Posted Date: 2024-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 189

Registration Number: NCT04589650

Locations: 🇺🇸
University of Wisconsin Hospital, Madison, Wisconsin, United States
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States

and more 11 locations

Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Mometasone furoate
Drug: QMF149
Drug: Standard of Care (Soc)

First Posted Date: 2020-10-19

Last Posted Date: 2023-10-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT04589663

Locations: 🇿🇦
Novartis Investigative Site, Cape Town, South Africa

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Failure

Interventions: Drug: Icenticaftor

First Posted Date: 2020-10-14

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT04587622

Locations: 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

Phase 2

Terminated

Conditions: Atrial Fibrillation

Interventions: Other: Placebo
Drug: HSY244

First Posted Date: 2020-10-09

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT04582409

Locations: 🇩🇪
Novartis Investigative Site, Frankfurt, Germany

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Phase 3

Active, not recruiting

Conditions: IgA Nephropathy

Interventions: Drug: LNP023
Drug: Placebo

First Posted Date: 2020-10-08

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 519

Registration Number: NCT04578834

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona, United States
🇺🇸
Kaiser Permanente, San Diego, California, United States

and more 20 locations

Special Drug Use-results Surveillance of Tabrecta Tablets

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Tabrecta tablets

First Posted Date: 2020-10-05

Last Posted Date: 2024-12-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 109

Registration Number: NCT04575025

Locations: 🇯🇵
Novartis Investigative Site, Toyama, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy